151 filings
Page 4 of 8
6-K
nkytgsxoe2
31 Mar 20
ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update
7:11am
6-K
le72nij
26 Feb 20
Current report (foreign)
7:52am
6-K
9hrmf
30 Jan 20
ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a
9:12am
6-K
e0bn6yvvq2s1c0
11 Dec 19
ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
8:46am
6-K
nrpfuo0zb8efmh
21 Nov 19
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
4:09pm
6-K
952 p09za1nde
12 Nov 19
PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements
4:03pm
6-K
rto98swmlu2ky8pg
17 Oct 19
ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares
4:26pm
6-K
3f506cigog36ol0rd
16 Oct 19
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
6:11am
6-K
pvtcj3j9w3m1g9u69
10 Oct 19
ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
8:05am
6-K
yoa2 fhwnhxkqe
9 Sep 19
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
4:30pm
6-K
0bzvvtafw
12 Aug 19
Current report (foreign)
4:04pm
6-K
eheqcgy5l1oxjja6kidj
7 Aug 19
Current report (foreign)
7:55am
6-K
s8a83 zudvajpfhujm5u
29 Jul 19
Current report (foreign)
4:03pm
6-K
ak7hg1ykl a24m
21 May 19
Current report (foreign)
4:03pm
6-K
nejw e2n0ec
8 May 19
Current report (foreign)
4:13pm
6-K
s7ovgmjla4b56 r2e
22 Apr 19
ProQR Announces Annual Meeting of Shareholders
12:00am
6-K
qtxjboy0y10owsnz
15 Apr 19
ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10
7:56am
6-K
w1hiozu z6058ky
26 Mar 19
ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
4:11pm
6-K
03yf7vyvi
11 Mar 19
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
5:02pm
6-K
2ygqcnbk u1
27 Feb 19
ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
8:27am